pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
THERAPEUTIC AREA
save

Pulmonology

Diseases of the lungs and respiratory tract.

also known as: respiratory, lung, pulmonary

🐶 often sniffed alongside

top 8
  • tagOncology207 co-mentions · 51 sources
  • tagNSCLC108 co-mentions · 47 sources
  • tagAdCom58 co-mentions · 53 sources
  • tagRecall49 co-mentions · 33 sources
  • tag510(k) Clearance35 co-mentions · 30 sources
  • tagCardiology25 co-mentions · 17 sources
  • tagPMA Approval23 co-mentions · 23 sources
  • tagInfectious Disease21 co-mentions · 20 sources
drugs
396
catalysts
22
news
2,254
companies
278

Top drugs

view all →
Marketed
CLEOCIN
$PFE · 127 catalysts
Marketed
clindamycin hydrochloride
Bacterial Pneumonia
90 catalysts
Marketed
NALBUPHINE HYDROCHLORIDE
Pain
84 catalysts
Marketed
DOXYCYCLINE HYCLATE
$AMRX · 49 catalysts
Marketed
methylprednisolone sodium succinate
Drug Hypersensitivity Reactions
48 catalysts
Marketed
METHYLPREDNISOLONE ACETATE
Giant Cell Arteritis (Temporal Arteritis/Cranial Arteriti…
41 catalysts
Marketed
METRONIDAZOLE
Bacterial Endocarditis
36 catalysts
Marketed
MEDROL
$PFE · 34 catalysts

🐶 Top companies

view all →
  • $PFEPFIZER INC
    9 products
  • Chiesi Farmaceutici SpA
    7 products
  • GlaxoSmithKline LLC
    7 products
  • $AZNASTRAZENECA PLC
    6 products
  • $MRKMerck & Co., Inc.
    6 products
  • $VERXVertex, Inc.
    6 products
  • Teva Pharmaceuticals USA Inc
    5 products
  • Aodh Lifesciences Pvt Ltd
    4 products

Recent catalysts

view all →
Apr 30, 2026
phase 2 completion
7mo ago
Huadong Hospital Affiliated to Fudan University — lidocaine (Phase II Trial Completion)
LIDOCAINE
→
Apr 30, 2026
phase 2 completion
$AZN178.84-1.88%
7mo ago
AstraZeneca Plc — tozorakimab (Phase II Trial Completion)
tozorakimab
→
Apr 30, 2026
phase 2 completion
$MRK137.78-3.90%
7mo ago
Merck & Co Inc — tulisokibart (Phase II Trial Completion)
tulisokibart
→
Apr 30, 2026
phase 2 completion
7mo ago
Brigham and Women's Hospital — dupilumab (Phase II Trial Completion)
dupilumab
→
Apr 30, 2026
phase 1 2 completion
7mo ago
Wuhan YZY Biopharma Co Ltd — M-701 (Phase I/II Trial Completion)
M-701
→
Apr 30, 2026
phase 1 completion
7mo ago
Beijing Minhai Biotechnology Co Ltd — pneumococcal (20-valent) vaccine (Phase I Trial Completion)
pneumococcal (20-valent) vaccine
→
Apr 30, 2026
phase 0 trial completion
7mo ago
Civil Aviation General Hospital — dexmedetomidine (Phase 0 Trial Completion)
dexmedetomidine
→
Apr 30, 2026
constraining patent expiry europe
$CPIX6.5700+13.28%
7mo ago
Cumberland Pharmaceuticals Inc — telavancin hydrochloride (Constraining Patent Expiry (Europe))
telavancin hydrochloride
→
Apr 29, 2026
phase 3 initiation
7mo ago
Chia Tai Tianqing Pharmaceutical Group Co Ltd — TQH-2722 (Phase III Trial Initiation)
TQH-2722
→
Apr 29, 2026
phase 2 initiation
7mo ago
Shenzhen Resproly Biopharmaceutical Co Ltd — RSN-0402 (Phase II Trial Initiation)
RSN-0402
→

Recent news

view all →
  • STAT+: Influential preventive services panel to meet for first time in more than a year↗
    stat · 7h ago
  • Merck scraps centerpiece of $2.7B ArQule buy after late-stage safety concerns↗
    biospace · 13h ago
  • STAT+: FDA discloses reasons for rejecting Summit drug↗
    stat · 13h ago
  • STAT+: Pharmalittle: We’re reading about Overton FDA nomination being yanked, a Merck setback, and more↗
    stat · 14h ago
  • FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSK↗
    biopharma dive · 14h ago
  • GSK nabs FDA greenlight for second lung cancer asset from Nuvalent buy↗
    biospace · 15h ago
  • Summit’s rejection letter reveals FDA’s deeper concerns about trial design, safety↗
    biospace · 15h ago
  • Summit’s rejection, Isomorphic’s record $5B raise, obesity and Alzheimer’s in the spotlight↗
    biospace · 17h ago
Data sources
openFDA · ClinicalTrials.gov · pharmadog Linker
last refreshed 2h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?